These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7927852)

  • 1. Predictive performance of two software packages (USC*PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients.
    Gauthier T; Lacarelle B; Marre F; Villard PH; Catalin J; Durand A
    Int J Biomed Comput; 1994 Jun; 36(1-2):131-4. PubMed ID: 7927852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Favereau JP; Gay R
    Int J Biomed Comput; 1994 Jun; 36(1-2):135-7. PubMed ID: 7927853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation.
    Lacarelle B; Pisano P; Gauthier T; Villard PH; Guder F; Catalin J; Durand A
    Int J Biomed Comput; 1994 Jun; 36(1-2):127-30. PubMed ID: 7927851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Gay C; Favereau JP; Gay R
    Eur J Clin Pharmacol; 1992; 43(4):435-6. PubMed ID: 1451727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a Bayesian method of amikacin dosing in intensive care unit patients with normal or impaired renal function.
    Lacarelle B; Granthil C; Manelli JC; Bruder N; Francois G; Cano JP
    Ther Drug Monit; 1987 Jun; 9(2):154-60. PubMed ID: 3617153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of amikacin in critically ill patients.
    Bressolle F; Gouby A; Martinez JM; Joubert P; Saissi G; Guillaud R; Gomeni R
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1682-9. PubMed ID: 8807062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Bayesian estimation for the prediction of an appropriate dosage regimen of amikacin.
    Garraffo R; Iliadis A; Cano JP; Dellamonica P; Lapalus P
    J Pharm Sci; 1989 Sep; 78(9):753-7. PubMed ID: 2585270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm.
    Debord J; Pessis C; Voultoury JC; Marquet P; Lotfi H; Merle L; Lachâtre G
    Fundam Clin Pharmacol; 1995; 9(1):57-61. PubMed ID: 7768489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing.
    Ryan AC; Carland JE; McLeay RC; Lau C; Marriott DJE; Day RO; Stocker SL
    Br J Clin Pharmacol; 2021 Mar; 87(3):1422-1431. PubMed ID: 32881037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models.
    Labaune JM; Bleyzac N; Maire P; Jelliffe RW; Boutroy MJ; Aulagner G; Putet G
    Biol Neonate; 2001 Aug; 80(2):142-7. PubMed ID: 11509814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of USC*PACK clinical programs to vancomycin in neutropenic patients.
    Kergueris MF; Le Normand Y; Jahan P; Milpied N
    Int J Biomed Comput; 1994 Jun; 36(1-2):163-5. PubMed ID: 7927856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen.
    Joubert P; Bressolle F; Gouby A; Douçot PY; Saissi G; Gomeni R
    Eur J Drug Metab Pharmacokinet; 1999; 24(1):39-46. PubMed ID: 10412890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in strategies for dosage regimen individualization.
    Marouani H; Woloch C; Benay S; Frances N; Iliadis A
    Curr Top Med Chem; 2012; 12(15):1669-77. PubMed ID: 22978335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computation of drug concentrations in endocardial vegetations in patients during antibiotic therapy.
    Maire P; Barbaut X; Vergnaud JM; el Brouzi M; Confesson MA; Pivot C; Chuzeville M; Ivanoff N; Brazier JL; Jelliffe RW
    Int J Biomed Comput; 1994 Jun; 36(1-2):77-85. PubMed ID: 7927862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic parameters of vancomycin in critically ill patients.
    Llopis-Salvia P; Jiménez-Torres NV
    J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of amikacin in intensive care unit patients.
    Fernández de Gatta MM; Mendez ME; Romano S; Calvo MV; Dominguez-Gil A; Lanao JM
    J Clin Pharm Ther; 1996 Dec; 21(6):417-21. PubMed ID: 9201569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the estimation of midazolam concentrations and pharmacokinetic parameters in intensive care patients using a bayesian pharmacokinetic software (PKS) according to sparse sampling approach.
    Bolon M; Bastien O; Flamens C; Paulus S; Salord F; Boulieu R
    J Pharm Pharmacol; 2003 Jun; 55(6):765-71. PubMed ID: 12841936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.